Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Tóm tắt
After completing this course, the reader will be able to:
Explain the biology of angiogenesis. Identify the role of VEGF in normal and tumor angiogenesis. Describe the key ways in which VEGF has been targeted in cancer therapy.
Access and take the CME test online and receive one hour of AMA PRA category 1 credit atCME.TheOncologist.com
The development of a vascular supply is a critical factor in the growth and metastatic spread of malignant tumors. Of the multitude of growth factors that regulate physiological and pathological angiogenesis, vascular endothelial growth factor (VEGF) is believed to be the most important. There is evidence that overexpression of VEGF is correlated with an adverse prognosis, at least in some tumors. Tumor-expressed VEGF is particularly attractive as a target for anticancer therapy because its angiogenesis-promoting activity is at the level of the endothelial cell and, compared with agents that directly target tumor cells, tumor penetration is less critical for VEGF inhibitors. Moreover, recent work has shown that inhibiting tumor angiogenesis increases the effectiveness of coadministered chemotherapy and radiotherapy. This suggests that drugs that target VEGF or its receptors can be combined with traditional treatment modalities to ensure maximum effectiveness. A variety of agents aimed at blocking VEGF or its receptor-signaling system are currently being developed for the treatment of cancer. Of these, bevacizumab, a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical development and has shown promising results in clinical trials.
Từ khóa
Tài liệu tham khảo
Algire, 1945, Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants, J Natl Cancer Inst, 6, 73, 10.1093/jnci/6.1.73
Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108
Ferrara, 2002, VEGF and the quest for tumour angiogenesis factors, Nat Rev Cancer, 2, 795, 10.1038/nrc909
Miller, 2001, Redefining the target: chemotherapeutics as antiangiogenics, J Clin Oncol, 19, 1195, 10.1200/JCO.2001.19.4.1195
Rosen, 2002, Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers, Cancer Control, 9, 36, 10.1177/107327480200902S05
Kerbel, 2000, Tumor angiogenesis: past, present and the near future, Carcinogenesis, 21, 505, 10.1093/carcin/21.3.505
Asahara, 1999, VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells, EMBO J, 18, 3964, 10.1093/emboj/18.14.3964
Lyden, 2001, Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth, Nat Med, 7, 1194, 10.1038/nm1101-1194
Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994
Pupa, 2002, New insights into the role of extracellular matrix during tumor onset and progression, J Cell Physiol, 192, 259, 10.1002/jcp.10142
Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7
Rak, 2000, Oncogenes and angiogenesis: signaling three-dimensional tumor growth, J Investig Dermatol Symp Proc, 5, 24, 10.1046/j.1087-0024.2000.00012.x
Li, 2000, Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models, J Natl Cancer Inst, 92, 143, 10.1093/jnci/92.2.143
Weidner, 1991, Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma, N Engl J Med, 324, 1, 10.1056/NEJM199101033240101
Kerbel, 2002, Clinical translation of angiogenesis inhibitors, Nat Rev Cancer, 2, 727, 10.1038/nrc905
Hasan, 2002, Intra-tumoural microvessel density in human solid tumours, Br J Cancer, 86, 1566, 10.1038/sj.bjc.6600315
Sledge, 2002, Angiogenesis and antiangiogenic therapy, Curr Probl Cancer, 26, 1, 10.1016/S0147-0272(02)70005-6
Ferrara, 1997, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/edrv.18.1.0287
Jussila, 2002, Vascular growth factors and lymphangiogenesis, Physiol Rev, 82, 673, 10.1152/physrev.00005.2002
Karkkainen, 2002, Lymphatic endothelium: a new frontier of metastasis research, Nat Cell Biol, 4, E2, 10.1038/ncb0102-e2
Toi, 2001, Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications, Lancet Oncol, 2, 667, 10.1016/S1470-2045(01)00556-3
Shibuya, 2001, Structure and function of VEGF/VEGF-receptor system involved in angiogenesis, Cell Struct Funct, 26, 25, 10.1247/csf.26.25
Neufeld, 1999, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J, 13, 9, 10.1096/fasebj.13.1.9
Shweiki, 1992, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature, 359, 843, 10.1038/359843a0
Shweiki, 1993, Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis, J Clin Invest, 91, 2235, 10.1172/JCI116450
Ferrara, 1996, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature, 380, 439, 10.1038/380439a0
Pepper, 1991, Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells, Biochem Biophys Res Commun, 181, 902, 10.1016/0006-291X(91)91276-I
Mandriota, 1995, Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells, J Biol Chem, 270, 9709, 10.1074/jbc.270.17.9709
Unemori, 1992, Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells, J Cell Physiol, 153, 557, 10.1002/jcp.1041530317
Lamoreaux, 1998, Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro, Microvasc Res, 55, 29, 10.1006/mvre.1997.2056
Alon, 1995, Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity, Nat Med, 1, 1024, 10.1038/nm1095-1024
Ferrara, 2001, Role of vascular endothelial growth factor in regulation of physiological angiogenesis, Am J Physiol Cell Physiol, 280, C1358, 10.1152/ajpcell.2001.280.6.C1358
Zachary, 2001, Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor, Am J Physiol Cell Physiol, 280, C1375, 10.1152/ajpcell.2001.280.6.C1375
Rousseau, 2000, Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells, Trends Cardiovasc Med, 10, 321, 10.1016/S1050-1738(01)00072-X
Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid, Science, 219, 983, 10.1126/science.6823562
Gabrilovich, 1998, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood, 92, 4150, 10.1182/blood.V92.11.4150
Pekala, 1990, Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin, J Biol Chem, 265, 18051, 10.1016/S0021-9258(17)44710-7
Mechtcheriakova, 2001, Specificity, diversity and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells, FASEB J, 15, 230, 10.1096/fj.00-0247com
Barleon, 1996, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1, Blood, 87, 3336, 10.1182/blood.V87.8.3336.bloodjournal8783336
Shen, 1998, Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro, J Biol Chem, 273, 29979, 10.1074/jbc.273.45.29979
List, 2001, Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies, The Oncologist, 6, 24, 10.1634/theoncologist.6-suppl_5-24
Lee, 2000, Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients, Eur J Cancer, 36, 748, 10.1016/S0959-8049(00)00003-4
Tokunaga, 1998, Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer, Br J Cancer, 77, 998, 10.1038/bjc.1998.164
Poon, 2001, Clinical implications of circulating angiogenic factors in cancer patients, J Clin Oncol, 19, 1207, 10.1200/JCO.2001.19.4.1207
Masood, 2001, Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors, Blood, 98, 1904, 10.1182/blood.V98.6.1904
Harmey, 2002, Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy, Bioessays, 24, 280, 10.1002/bies.10043
Tran, 2002, A role for survivin in chemoresistance of endothelial cells mediated by VEGF, Proc Natl Acad Sci USA, 99, 4349, 10.1073/pnas.072586399
Saito, 1998, Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue, Br J Cancer, 78, 1573, 10.1038/bjc.1998.725
Pegram, 2002, Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor, Semin Oncol, 29, 29, 10.1053/sonc.2002.34053
Kerbel, 2001, Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results, J Clin Oncol, 19, 45S
Marx, 2002, Cancer research. Obstacle for promising cancer therapy, Science, 295, 1444, 10.1126/science.295.5559.1444a
Yu, 2002, Effect of p53 status on tumor response to antiangiogenic therapy, Science, 295, 1526, 10.1126/science.1068327
Jain, 2001, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy, Nat Med, 7, 987, 10.1038/nm0901-987
Jain, 1989, Delivery of novel therapeutic agents in tumors: physiological barriers and strategies, J Natl Cancer Inst, 81, 570, 10.1093/jnci/81.8.570
Teicher, 1994, Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, Int J Cancer, 57, 920, 10.1002/ijc.2910570624
Lee, 2000, Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions, Cancer Res, 60, 5565
Gorski, 1998, Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin, Cancer Res, 58, 5686
Hurwitz, 2004, Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial, N Engl J Med